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OBJECTIVE: This study aims to describe the distributions
of lipid lowering and attainment of National Cholesterol
Education Panel goals and apply these distributions to
pharmacoeconomic models for specific populations.
METHODS: Lipid results and costs from a series of
treat-to-target studies of statins (atorvastatin, fluvastatin,
lovastatin, pravastatin, and simvastatin) were used to es-
timate distributions of lipid-lowering effects and cost for
patients.
RESULTS: Almost 1000 patients were enrolled in one of
three trials: patients with risk factors for coronary heart
disease (CHD) in the United States, CHD in the United
States, and CHD or peripheral vascular disease (PVD) in
Europe. Lipid-lowering effects are not normally distrib-
uted and are not consistent among statins. Results for
two statins were skewed right and results for three statins
were skewed left. As a result, costs associated with lipid-
lowering treatment are not normally distributed and are
not equal among statins.
CONCLUSIONS: Models based upon clinical and trials
and associated pharmacoeconomic analyses may be biased
if they use only published data without an understanding
of the underlying distributions of these data. In a set of
populations with higher than average lipid levels (lower
than average lipid levels), models that rely on means from
published studies would underestimate (overestimate) the
differences among statins.
DRUG POLICY RESEARCH
DP1
EFFECT OF DEMOGRAPHICS ON THE COST 
OF PHARMACEUTICALS IN A PRIVATE 
THIRD-PARTY PRESCRIPTION PROGRAM
Momin SR, Larrat EP, Harlow LL
University of Rhode Island, Kingston, RI, USA
OBJECTIVES: The primary objective of this study was to
compare variance in cost of pharmaceuticals explained
by demographic variables with variance explained by
plan-characteristics within various therapeutic categories
using prescription claims data. The secondary objective
was to examine differences in utilization among demo-
graphic variables after controlling for covariates.
METHODS: Data were obtained from 1996 prescription
claims information for the commercial population ad-
ministered by a Rhode Island–based PBM. There were
29,211 subscribers representing 64,815 enrollees (mean
age 31.5) eligible during 1996. Subscribers were mainly
employed in health (39.8%), sales and services (17.7%),
and manufacturing (10.3%). Six therapeutic categories
were analyzed. Statistical analyses utilizing multiple re-
gression and analysis-of-covariance were performed.
RESULTS: Plan-characteristics out-performed demographic
variables 16-fold for all drug categories combined in ex-
plaining variance in cost of pharmaceuticals. Significant
differences (p  0.0001) in utilization were found among
demographic variables after controlling for average whole-
sale price and days supply.
CONCLUSIONS: The results obtained in this study have
practical significance in the determination of capitation
rates when utilization history of prospective members is un-
available. In this situation, PBMs may have to set capita-
tion rates based solely on eligibility data. PBMs contract
with commercial clients to provide pharmacy benefits to
their employees irrespective of their occupation. Significant
differences in utilization among the members based on
place of employment suggest that benefit managers should
consider differentiating capitation rates according to their
clients’ businesses. Finally, this study indicated that com-
mercial members residing in Tennessee had the lowest level
of drug utilization among all states evaluated. The fact that
one PBM manages over 80% of the TennCare prescription
program along with a significant commercial client base
suggests that “spillover-effect” may exist.
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OBJECTIVE: Hospitalization is the single greatest cost in
the treatment of asthma. Various factors, such as type of
healthcare insurance, may be related to asthma hospital-
ization rates. This study assessed the hospitalization rates
for asthmatics subsequent to an emergency room (ER)
visit among payer types.
METHODS: Medical claims from the Premier PCD data-
base were screened to identify adults (ages 18–65) visit-
ing an ER for treatment of asthma (ICD-9-CM: 493)
from October 1, 1996 to September 30, 1997. Subjects
were then classified into two groups: ER only and ER
and hospitalization. Payers identified from each claim
were grouped into these categories: Managed Care, In-
demnity Plans, Medicaid, Medicare, and Self-Pay.
RESULTS: Of the 2738 patients who met the inclusion
criteria, only 773 (28%) required hospitalization. Self-
Pay patients were the least likely to be hospitalized
(12.6% hospitalization rate) while Indemnity and Man-
aged Care patients were hospitalized at a rate of 23.4%
and 33.3%, respectively. After controlling for age, race,
gender, and comorbidities, Indemnity patients were ap-
proximately 65% as likely to be hospitalized as Managed
Care patients (OR  0.650; 95% CI 0.493–0.856). Of
the hospitalized patients, the Self-Pay patients had the
shortest hospital stay and lowest total cost (2.98 days,
$2417.72). Managed Care patients had lower total costs
and shorter hospital stays than Indemnity patients, how-
ever the differences among the groups were not signifi-
cant. No significant differences in mean age or APR-DRG
